Business Wire

Zambon Announces Publication of Phase 3 PROMIS I and II Study Results in The Lancet Respiratory Medicine Showing Efficacy Results of CMS I-neb in Patients with Non-Cystic Fibrosis Bronchiectasis Colonized with P. aeruginosa

13.9.2024 12:00:00 EEST | Business Wire | Press release

Share

Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve people’s health and the quality of patients’ lives, today announced the online publication of its Phase 3 PROMIS-I and PROMIS-II studies in The Lancet Respiratory Medicinejournal. The PROMIS studies assessed the efficacy and safety of inhaled colistimethate sodium administered via the I-neb® Adaptive Aerosol Delivery System (“CMS I-neb”) as a treatment to reduce the frequency of pulmonary exacerbations in patients with Non-Cystic Fibrosis Bronchiectasis (NCFB) chronically colonized with P. aeruginosa over 12 months, compared to placebo.

“The publication of these pivotal data in The Lancet Respiratory Medicine represents an important milestone in our commitment to developing innovative therapies for patients with severe respiratory diseases,” said Paola Castellani, Chief Medical Officer and R&D Head at Zambon. “For patients with NCFB, a condition with no approved treatment options, the results from the PROMIS program highlight the potential of CMS I-neb to improve outcomes and quality of life. We look forward to working with regulatory authorities on a path to making this important treatment available to patients as quickly as possible."

Chronic infection with P. aeruginosa is associated with more severe disease, accelerated lung function decline, increased exacerbations, hospitalizations and a higher mortality rate.i The PROMIS trials represent the first large-scale, double-blind, placebo-controlled studies of inhaled colistimethate sodium, a widely used antibiotic in Europe for Cystic Fibrosis.

The published study results are based upon the two global Phase 3, multicenter, randomized, double-blind, placebo-controlled PROMIS-I and PROMIS-II trials in adult patients with bronchiectasis chronically colonized with P. aeruginosa with a history of at least two exacerbations requiring oral antibiotics or one requiring intravenous antibiotics in the previous year. Patients were randomized (377 in PROMIS-I and 287 in PROMIS-II) to receive inhaled colistimethate sodium or placebo via the I-neb device twice daily for up to 12 months. The primary efficacy endpoint was the annual pulmonary exacerbation rate. Key secondary efficacy endpoints were time to first exacerbation, quality of life, change in P. aeruginosa density, severe exacerbation rate, and time to first severe exacerbation.

Key Findings from PROMIS-I and PROMIS-II:

  • In the PROMIS-I trial, the primary endpoint of a significant reduction in annual pulmonary exacerbation rate was achieved, with a 39% reduction in exacerbations (rate ratio 0.61; 95% CI 0.46–0.82; p=0.0010) compared with placebo.
  • Severe exacerbations were reduced by 59%, and patients treated with CMS I-neb experienced a clinically importantii improvement in quality of life, as measured by the St. George’s Respiratory Questionnaire, and a reduction of P. aeruginosa density.
  • The PROMIS-II study had to be stopped prematurely due to the COVID-19 pandemic and the results were not satisfactory. However, when a sub analysis of the PROMIS-II pre-pandemic period was done, the results were consistent with those obtained in the PROMIS-I trial.
  • Both trials reported good tolerability, with no major safety issues identified. Bronchospasm was rare, occurring in less than 5% of patients.

“The results of the PROMIS program represent an important breakthrough for patients with NCFB, a population that has long suffered from chronic respiratory infections without any approved treatments. For the first time, we have robust evidence showing that CMS I-neb can significantly reduce exacerbations and improve quality of life in patients with NCFB and chronic P. aeruginosa infection, offering hope where there were previously limited options,” said Dr. Charles Haworth, Respiratory Physician at the Cambridge Centre for Lung Infection at Royal Papworth Hospital, and PROMIS trials Chief Investigator.

“These findings underscore the importance of inhaled antibiotics, such as CMS I-neb, in reducing exacerbations and improving outcomes in patients with NCFB chronically infected with P. aeruginosa. Chronic bronchial infection plays a key role in driving inflammation and airway damage in bronchiectasis, and reducing exacerbations has been linked to better prognosis, quality of life and lung function,” said Professor James Chalmers, Professor of Respiratory Research at the University of Dundee and PROMIS Investigator.

The PROMIS clinical program has received FDA Qualified Infectious Disease Product (QIDP), Fast Track and Breakthrough designations for the reduction in the incidence of pulmonary exacerbations in adult NCFB patients colonized with P. aeruginosa.

About the PROMIS Development Program
The PROMIS-I and PROMIS-II are multicenter, randomized, double-blind, placebo-controlled trials investigating the efficacy and safety of inhaled colistimethate sodium administered via the I neb® Adaptive Aerosol Delivery System (CMS I-neb®) in adults with non-cystic fibrosis bronchiectasis chronically infected with P. aeruginosa. The primary objective of both trials was to investigate the annual rate of pulmonary exacerbations in patients receiving CMS I-neb® administered twice daily versus placebo.

Secondary endpoints included the time to first pulmonary exacerbation, the annual rate of severe pulmonary exacerbations, the time to first severe pulmonary exacerbation, quality of life measured by the St. George’s Respiratory Questionnaire and the Quality of Life Questionnaire-Bronchiectasis (QOL-B), the number of exacerbation-free days, P. aeruginosa density and susceptibility, any developing resistance, and overall safety and tolerability.

The PROMIS-I trial enrolled 377 patients in 12 countries, including Australia, Belgium, Germany, Greece, Israel, Italy, Netherlands, New Zealand, Portugal, Spain, Switzerland, and the United Kingdom. The PROMIS-II trial enrolled 287 patients in 12 countries, including Argentina, Australia, Canada, Germany, Greece, Israel, Italy, New Zealand, Poland, Portugal, France, and the United States.

About NCFB
Non-cystic fibrosis bronchiectasis (NCFB) is a chronic lung disease characterized by recurrent infection, inflammation, persistent cough, and production of sputum, and its prevalence is increasing worldwide.
NCFB has a progressive course primarily determined by the rate of exacerbations, many of which are related to Pseudomonas aeruginosa. Consequently, research efforts directed to treat infection by P. aeruginosa and its associated acute exacerbations remain a clinical priority.iii
The objectives of treatment in bronchiectasis are to prevent exacerbations, reduce symptoms, improve quality of life, and stop disease progression.
Cough and sputum production, along with breathlessness, are the most frequent symptoms, but rhinosinusitis, fatigue, hemoptysis, and thoracic pain are also common.
Over the last decade, the prevalence of NCFB has increased by 40% and is now estimated to be up to 566 per 100,000 people, making it the third most common chronic airways disease.iv
The incidence of NCFBappears to be rising too, particularly in women and older individuals.

About Colistimethate sodium (CMS)
Colistimethate sodium (CMS) is a pro-drug (the form used for inhalation therapy) of the antibiotic colistin.
Colistin is a polymyxin antibiotic derived from Bacillus polymyxa var. colistinus.
Polymyxin antibiotics are surface active agents that act by binding to and changing the permeability of the bacterial cell membrane, causing bacterial cell death.
Colistin is an active agent against aerobic Gram-negative pathogens that can cause life-threatening infections, such as P. aeruginosa.
Colistin remains one of the few active antimicrobial agents against multi-drug-resistant Gram-negative bacteria. It is currently considered one of the last therapeutic options for infections such as carbapenem-resistant P. aeruginosa.

About Zambon SpA
Zambon SpA is a multinational pharmaceutical company established in 1906 in Vicenza, whose history is founded on the values of an Italian family committed to innovating cure & care to improve patients’ lives. It employs more than 2,500 people worldwide, is present in 23 countries in Europe, America and Asia, and has production facilities in Italy, Switzerland, China and Brazil. Thanks to its innovative, quality products commercialized in 87 countries, Zambon Spa reported a revenue of 843 million euros in 2023. Alongside the three historical therapeutic areas - diseases of the respiratory system, urinary tract infections and pain treatment – Zambon is focused on developing treatments for neurodegenerative diseases such as Parkinson's or rare diseases such as cystic fibrosis, BOS, to which is linked the major 2019 acquisition of Breath Therapeutics, and NCFB. For further information on Zambon please visit www.zambon.com.

____________________________
i
Finch S, McDonnell MJ, Abo-Leyah H, Aliberti S, Chalmers JD. A Comprehensive Analysis of the Impact of Pseudomonas aeruginosa Colonization on Prognosis in Adult Bronchiectasis. Ann Am Thorac Soc Vol 12, No 11, pp 1602–1611, Nov 2015

ii McLeese RH, Spinou A, Alfahl Z, et al. Psychometrics of health-related quality of life questionnaires in bronchiectasis: a systematic review and meta-analysis. Eur Respir J 2021; 58:2100025.

iii Severiche-Bueno D, Gamboa E, Reyes LF, Chotirmall SH. Hot topics and current controversies in non-cystic fibrosis bronchiectasis. Breathe 2019; 15: 286–295

iv Thornton, Christina S., Somayaji, Ranjani, Lim, Rachel K. Assessment of factors and interventions towards therapeutic adherence among persons with non-cystic fibrosis bronchiectasis. ERJ Open Research. 2022; 2022-10-01, 00340-2022. 10.1183/23120541.00340-2022. https://bit.ly/3TcvnqX

View source version on businesswire.com: https://www.businesswire.com/news/home/20240912235933/en/

Contacts

For more information, please contact: media@zambongroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Plural Raises €1bn to Back the Frontier Founders Building a New Europe16.11.2026 11:00:00 EET | Press release

Plural, the early-stage investment fund led by founders and operators, has raised €1bn to back the founders Europe is counting on. Plural’s ambition is to have GDP-level impact on Europe. It backs founders building what a changing world needs most over the next decade: energy, AI infrastructure, defence, health and other frontier technologies. For two decades, the bulk of the world’s most valuable technology companies have been built in the US and China, leaving Europe a customer rather than a creator. That has cost the continent prosperity and bargaining power. Rapid technological change now gives Europe a chance to catch up, and Plural believes the continent has the founders, research and momentum to build many more global companies of its own. Global companies, built from Europe When Plural launched in 2022, frontier founders working on defence, energy, space and AI infrastructure in Europe struggled to raise capital. Plural’s partners backed startups in these sectors early, and Plu

SES and ITU Expand Partner2Connect Digital-learning Initiative to 30 African Schools16.11.2026 10:36:00 EET | Press release

SES, a leading space solutions company, announced progress on its commitment to the International Telecommunication Union's (ITU) Partner2Connect Digital Coalition, through which the company is connecting 30 schools across Malawi, Burundi, Zambia, and Zimbabwe by the end of 2026. The initiative, developed in cooperation with the ITU Telecommunication Development Bureau, aims to expand access to digital education and online resources for an estimated 20,000 to 30,000 students and teachers in underserved and remote communities. Through SES’s solutions, the coalition has given students and educators access to online learning platforms, teacher-training resources and collaboration tools. These resources help schools strengthen digital skills and expand learning opportunities to allow students better participate in the future economy. “Digital inclusion depends on more than reaching remote locations. It requires partners that can translate commitments into connectivity that communities can

Regnology and ActiveViam Partner to Bring the Same Granular, Explainable Risk Intelligence to Banks and Their Supervisors16.11.2026 10:00:00 EET | Press release

Regnology, a leading global technology provider at the intersection of regulatory reporting, risk management, finance, and supervisory technology, today announced a strategic partnership with ActiveViam, the provider of Atoti, the AI-native enterprise risk intelligence platform for capital markets. The partnership embeds Atoti as the real-time risk aggregation and analytics engine in Regnology Risk Hub, and will extend it to supervisory authorities through Regnology Supervisory Hub. Regnology is the only provider whose offering serves both the regulated and their regulators, with more than 15,000 financial institutions and more than 100 authorities as clients. Markets and depositors now move within days, and the questions that follow rarely fit a predefined report. During the 2023 market turmoil, supervisors faced significant delays in accessing liquidity data and relied on daily calls with bank treasurers, according to the European Banking Authority. Banks and supervisors share the co

Don’t Let Europe’s Nicotine Black Market Go Unchecked16.11.2026 09:06:00 EET | Press release

On the UN International Day against Transnational Organised Crime, Crime Stoppers International (CSI) launched Don’t let it go unchecked, a campaign asking the public to help break Europe’s black market in vapes and nicotine pouches by reporting illegal sellers anonymously. This matters more than ever. Illegal vapes and nicotine pouches are flooding into Europe. The sellers don’t care how they’re made or who buys them, and don’t pay taxes. Nobody knows who's behind them, except the criminal networks cashing in. The illegal trade in nicotine products is funding the same criminal networks that traffic fake medicine, illicit drugs and weapons, and putting untested products into the hands of children. Hayley van Loon, CEO of Crime Stoppers International, said: “It’s just a vape. It’s just a pouch. That is exactly what the criminals selling them want you to think. Nobody knows what’s in these products. They’re made in illegal factories with no safety standards and sold to anyone, including

Sofinnova Partners Closes €725M Crossover II Fund16.11.2026 09:00:00 EET | Press release

Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Crossover II at €725 million ($815 million USD). The fund exceeded its original target, reflecting growing confidence in Sofinnova’s strategy of backing late-stage life sciences companies with the potential to become global leaders. Sofinnova Crossover II will focus primarily on European clinical-stage biopharma and medtech companies seeking capital to advance toward commercialization. It will also invest in best-in-class companies in the United States and other international markets. Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said: "The scale of this fund reflects both the maturity of the European life sciences ecosystem and the rising demand for capital that can help companies to reach global markets. Europe is producing a growing number of world-class life sciences companies, and we believ

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye